|
1.Date of the shareholders meeting resolution:2025/05/29
2.Name and title of the director with permission to engage in
competitive conduct:
Directors：
Representative of China Chemical & Pharmaceutical Co., Ltd./
Wang Hsieh, I-Chen
Representative of China Chemical & Pharmaceutical Co., Ltd./
Wang, Hou-Kai
Representative of Wang Ming-Ning Memorial Foundation. /
Wang, Hou-Jie
Representative of Wang Ming-Ning Memorial Foundation. /
Wu, Shih-Hsuan
Independent Directors：
Wang, Kuo-Chiang
Kuan, Arthur
Lee, Ming-Jye
3.Items of competitive conduct in which the director is permitted
to engage:
(1)Directors: Representative of China Chemical & Pharmaceutical
Co., Ltd./Wang Hsieh, I-Chen
A.Chairman of Cenra Inc. (Wang Ming-Ning Memorial Foundation
legal representative)
B.Chairman of China Chemical & Pharmaceutical Co., Ltd. (Cenra
Inc. legal representative)
C.Chairman of Chunghwa Yuming Healthcare Co., Ltd. (China
Chemical & Pharmaceutical Co., Ltd. legal representative)
D.Chairman of Chunghwa Senior Care Co., Ltd. (China Chemical
& Pharmaceutical Co., Ltd. legal representative)
E.Chairman, President of Tairung Development Co., Ltd.
F.Chairman of HU-YU Co., Ltd.
G.Chairman of Majiade Enterprises Co., Ltd.
H.Supervisor of Sela Holdings Inc.
I.Director of Suzhou Chung-Hwa Chemical Pharmaceutical
Industrial Co., Ltd.
J.Chairman of Wang Ming-Ning Memorial Foundation Chairman
(2)Directors:Representative of China Chemical & Pharmaceutical
Co., Ltd./Wang, Hou-Kai
A.Chairman of Sela Holdings Inc. Chairman
B.Chairman, CEO of Cenra Inc. (Sela Holdings Inc. legal
representative)
C.Director of of Sino-Japan Chemical Co., Ltd. (China Chemical
& Pharmaceutical Co., Ltd. legal representative)
D.Director of China Chemical & Pharmaceutical Co., Ltd. (Cenra
Inc. legal representative)
E.Director of Chunghwa Yuming Healthcare Co., Ltd. (China
Chemical & Pharmaceutical Co., Ltd. legal representative)
F.Director of Chunghwa Senior Care Co., Ltd. (China Chemical &
Pharmaceutical Co., Ltd. legal representative)
G.Director of Tairung Development Co., Ltd. (China Chemical &
Pharmaceutical Co., Ltd. legal representative)
H.Supervisor of Majiade Enterprises Co., Ltd.
I.Director of Suzhou Chung-Hwa Chemical Pharmaceutical
Industrial Co., Ltd.
J.Director of Wang Ming-Ning Memorial Foundation Chairman
(3)Directors:Representative of Wang Ming-Ning Memorial
Foundation. /Wang, Hou-Jie
A.Director of Cenra Inc.
B.Director of Tairung Development Co., Ltd.
C.Director of Suzhou Chung-Hwa Chemical Pharmaceutical
Industrial Co., Ltd.
D.Executive Director of Shanghai Yuhou Trading Co., Ltd.
(formerly known as Beifu (Shanghai) Trading Co., Ltd.)
(4)Directors:Representative of Wang Ming-Ning Memorial
Foundation. /Wu, Shih-Hsuan
A.Director of China Chemical & Pharmaceutical Co., Ltd.
(Cenra Inc. legal representative)
B.Director of Chunghwa Yuming Healthcare Co., Ltd.
(China Chemical& Pharmaceutical Co., Ltd. legal
representative)
C.Director of Suzhou Chung-Hwa Chemical Pharmaceutical
Industrial Co., Ltd.
D.Vice President of Operational Performance/Strategic
Procurement, Cenra Inc.
(5)Independent Directors：Wang, Kuo-Chiang
A.Chairman of Lien Chieh Management and Consultation
Co., Ltd.
B.Independent Director, Convener of Compensation and
Remuneration Committee, and Convener of Audit Committee,
Partner Tech Corp.
C.Independent Director, Convener of Compensation and
Remuneration Committee, and Convener of Audit Committee,
Hill Source Holdings Limited (KY Company)
D.Independent Director, Convener of Compensation and
Remuneration Committee, and Convener of Audit Committee,
Otobrite Electronics Inc.
E.Assistant Professor of National Yang Ming Chiao Tung University
(6)Independent Directors：Kuan, Arthur
Chief Executive Officer and Chairman, CG Oncology (Eternal
Facial Biotechnology Co., Ltd.)
(7)Independent Directors：Lee, Ming-Jye
Vice President of the Young Women’s Christian Association
4.Period of permission to engage in the competitive conduct:
During the tenure of director post.
5.Circumstances of the resolution (please describe the results of
voting in accordance with Article 209 of the Company Act):
Approved by more than two-thirds of voting rights of attending
shareholders, who hold more than half of the total number of shares
issued.
6.If the permitted competitive conduct belongs to the operator of a
mainland China area enterprise, the name and title of the directors
(if it is not the operator of a Mainland-area enterprise, please enter
“N/A” below):
Representative of China Chemical & Pharmaceutical Co., Ltd./
Wang Hsieh, I-Chen
Representative of China Chemical & Pharmaceutical Co., Ltd./
Wang, Hou-Kai
Representative of Wang Ming-Ning Memorial Foundation. /
Wang, Hou-Jie
Representative of Wang Ming-Ning Memorial Foundation. /
Wu, Shih-Hsuan
7.Company name of the mainland China area enterprise and the
director's position in the enterprise:
(A)Representative of China Chemical & Pharmaceutical Co., Ltd.
/ Wang Hsieh, I-Chen: Director of Suzhou Chung-Hwa Chemical
Pharmaceutical Industrial Co., Ltd.
Representative of China Chemical & Pharmaceutical Co., Ltd.
/ Wang, Hou-Kai: Director of Suzhou Chung-Hwa Chemical
Pharmaceutical Industrial Co., Ltd.
Representative of Wang Ming-Ning Memorial Foundation.
/ Wang, Hou-Jie: Director of Suzhou Chung-Hwa Chemical
Pharmaceutical Industrial Co., Ltd.
Representative of Wang Ming-Ning Memorial Foundation.
/ Wu, Shih-Hsuan: Director of Suzhou Chung-Hwa Chemical
Pharmaceutical Industrial Co., Ltd.
(B)Representative of Wang Ming-Ning Memorial Foundation.
/ Wang, Hou-Jie: Executive Director of Shanghai Yuhou Trading
Co., Ltd. (formerly known as Beifu (Shanghai) Trading Co., Ltd.)
8.Address of the mainland China area enterprise:
(A)Suzhou Chung-Hwa Chemical Pharmaceutical Industrial Co., Ltd.:
No. 66, Yong'an Road, Suzhou High-tech Zone, Jiangsu Province,China
(B)Shanghai Yuhou Trading Co., Ltd. (formerly known as Beifu
(Shanghai) Trading Co., Ltd.): No. 777 Hongqiao Road, Xuhui
District, Shanghai, China Room 1605
9.Operations of the mainland China area enterprise:
(A)Production and distribution of pharmaceutical preparations and
healthcare supplies.
(B)Medical device management and cosmetics sales.
10.Impact on the company's finance and business: None
11.If the directors have invested in the mainland China area enterprise,
the monetary amount of the investment and their shareholding ratio:
N/A
12.Any other matters that need to be specified: None
|
